Cizzle Bio Inc, a biotechnology company advancing biomarker blood tests for early cancer detection, announced on Wednesday its participation in the 18th Annual Next Generation Dx Summit in Washington, D.C.

On Monday, Dr. Lary A. Robinson, director of the Lung Cancer Early Detection (LEAD) Center at Moffitt Cancer Center, presented 'Potential of the CIZ1B Biomarker to Redefine Early Lung Cancer Detection,' examining the potential role of CIZ1B in lung cancer detection and patient management and providing an overview of the clinical study underway at Moffitt.

CIZ1B is being evaluated at Moffitt Cancer Center in patients with identified lung nodules. The study is assessing its potential to distinguish malignant from benign nodules, stratify recurrence risk after curative treatment and support surveillance for recurrence or second primary lung cancers. Results from blood collected at initial evaluation are compared with clinical diagnoses, with serial testing also studied during follow-up.

Dr. Robinson discussed challenges in early lung cancer detection, including limited participation in low-dose CT (LDCT) screening and uncertainty associated with indeterminate pulmonary nodules. Approximately 1.6 million lung nodules are identified annually in the United States, underscoring the need for tools to help clinicians determine which nodules warrant further evaluation.

Developed from 30 years of research at the University of York, CIZ1B is a blood-based biomarker associated with early-stage lung cancer. A recently published study in The Journal of Applied Laboratory Medicine evaluating the scalable ELISA assay reported sensitivity of approximately 94% and a negative predictive value of 97%.

Cizzle Bio commercially launched the CIZ1B Biomarker Blood Test for licensed healthcare providers in the Dallas-Fort Worth and San Antonio markets in July 2026, marking the first phase of the company's planned national rollout strategy.